The CMS published the much-anticipated Overall Hospital Quality Star Ratings on Wednesday after industry stakeholders and Congress pressured the agency to continue to delay their release.
Drugmaker Teva has agreed to divest a record 79 generic drugs to satisfy the Federal Trade Commission, which had challenged its proposed acquisition of Allergan's generic pharmaceutical business as anticompetitive.
A list of the 20 largest healthcare merger-and-acquisition deals through June 2016, ranked by announced purchase price based on Modern Healthcare reporting. Source: Modern Healthcare Mergers & Acquisitions premium database. Published July 25, 2016, p. 34.
Medicare's accelerating move to bundled payments for episodes of care will drive hospitals and physicians to pay more attention to what happens to patients after they leave.
Less than a week after finding out the U.S. Justice Department would seek to block its acquisition of Cigna Corp., Anthem said Wednesday that its second-quarter profit fell more than 9% year over year and it lowered its earnings projections for the rest of the year.
Two key players in the passage of the ACA warn that if Donald Trump becomes president, he and congressional Republican leaders could indeed abolish key elements of the law and roll back the insurance expansions and consumer protections.
Shareholders at McKesson's annual meeting sided with the board and management in rejecting proposals to require greater disclosure of political contributions and limit golden parachutes for senior executives in a change of ownership.
Huron Consulting Group is continuing a shopping spree by announcing its intent to acquire a healthcare IT consultant whose clients include Allscripts, Athenahealth, Cerner and Epic. Terms of Huron's fifth pickup in less than a year were undisclosed but the current target is Healthcare Services...
Latest guidelines released Tuesday by the U.S. Preventive Services Task Force have upheld its 2009 recommendations that found there was not enough evidence to assess the benefits or harms in conducting visual examinations to screen for skin cancer in patients at moderate risk.
Lilly CEO John Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products. David Ricks, president of its biomedicines business, will replace Lechleiter in January.
We asked readers to vote for up to 10 innovations. These are the 25 that garnered the most votes, including storefront healthcare, bionic limbs and primary-care access.